We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$302M
Cap. Flow
+$392M
Cap. Flow %
37.44%
Top 10 Hldgs %
55.13%
Holding
117
New
33
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$17.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$17.6M
3
NUVL
Nuvalent
NUVL
+$13.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$11.3M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$8.63M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$12.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$11.5M
3
SYRE icon
Spyre Therapeutics
SYRE
+$7.13M
4
ARWR icon
Arrowhead Research
ARWR
+$5.64M
5
SLNO
Soleno Therapeutics
SLNO
+$3.9M

Sector Composition

Rank Sector Weight
1 Healthcare 55.37%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$224M 21.36%
+400,000
New +$235M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$59.8M 5.71%
+300,000
New +$65.1M
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.6B
$44.6M 4.25%
1,328,175
+166,938
+14% +$6.34M
APGE icon
4
Apogee Therapeutics
APGE
$10.1B
$43M 4.1%
1,151,199
+219,471
+24% +$8.49M
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$40.5M 3.87%
500,000
-250,000
-33% -$22.3M
VRNA
6
DELISTED
Verona Pharma
VRNA
$39M 3.73%
615,000
-45,000
-7% -$2.69M
ACLX
7
DELISTED
Arcellx
ACLX
$34.8M 3.32%
530,000
+105,000
+25% +$7.11M
ALKS icon
8
Alkermes
ALKS
$8.79B
$33M 3.15%
1,000,000
-100,000
-9% -$3.26M
NUVL
9
DELISTED
Nuvalent
NUVL
$32.6M 3.11%
460,000
+175,000
+61% +$13.7M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.8B
$26.5M 2.53%
80,000
-2,500
-3% -$821K
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$22.2M 2.12%
1,546,662
+450,738
+41% +$7.38M
AMGN icon
12
CALL
Amgen
AMGN
$198B
$21.8M 2.08%
70,000
+40,000
+133% +$11.8M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$37.3B
$21.5M 2.05%
1,400,000
– –
PTGX icon
14
Protagonist Therapeutics
PTGX
$9.06B
$19.3M 1.85%
400,000
+270,000
+208% +$11.3M
TVTX icon
15
Travere Therapeutics
TVTX
$5.27B
$19.2M 1.83%
1,070,000
+870,000
+435% +$17.7M
MLYS icon
16
Mineralys Therapeutics
MLYS
$2.39B
$17.5M 1.67%
1,100,000
+750,000
+214% +$8.63M
SPY icon
17
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$16.8M 1.6%
+30,000
New +$17.6M
ALNY icon
18
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
$14.9M 1.42%
+55,000
New +$14.1M
WVE icon
19
Wave Life Sciences
WVE
$1.12B
$14.7M 1.41%
1,825,000
+325,000
+22% +$3.55M
MRUS
20
DELISTED
Merus
MRUS
$13.6M 1.29%
321,962
-67,279
-17% -$2.93M
AXSM icon
21
Axsome Therapeutics
AXSM
$11.8B
$11.7M 1.11%
100,000
+25,000
+33% +$2.85M
ESTA icon
22
Establishment Labs
ESTA
$2.72B
$11.4M 1.09%
280,000
+555
+0.2% +$20.7K
INSM icon
23
Insmed
INSM
$23.5B
$10.7M 1.02%
140,000
+90,000
+180% +$6.88M
BBIO icon
24
BridgeBio Pharma
BBIO
$15.9B
$10.4M 0.99%
300,000
+100,000
+50% +$3.37M
NRIX icon
25
Nurix Therapeutics
NRIX
$2.4B
$9.63M 0.92%
810,669
-129,414
-14% -$2.16M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Affinity Asset Advisors held 117 positions worth $1.05B, up 40% from $746M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Affinity Asset Advisors deployed $392M of net new capital in Q1 2025, opening 33 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 78% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $11.5M trimmed.

  • Affinity Asset Advisors's largest Q1 2025 buy was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
  • Affinity Asset Advisors added most to Travere Therapeutics in Q1 2025, an estimated $17.7M increase.
  • Affinity Asset Advisors's biggest Q1 2025 reduction was Crinetics Pharmaceuticals, cutting an estimated $11.5M.
  • Affinity Asset Advisors fully exited Arvinas in Q1 2025, selling an estimated $12.1M.
  • Affinity Asset Advisors's ten largest holdings make up 55% of its $1.05B portfolio in Q1 2025.
  • Affinity Asset Advisors opened 33 new positions and closed 19 in Q1 2025.
  • Affinity Asset Advisors's portfolio value rose 40% quarter-over-quarter to $1.05B.

Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.